The Aged Immune Cells Quietly Driving Liver Disease From Within
Hidden inside the livers of people with fatty liver disease is a population of immune cells that have biologically aged — and are fuelling a slow, smouldering inflammation that makes everything worse…
Published in Nature Aging, the research describes a subset of macrophages — immune cells that normally clean up debris and regulate inflammation — marked by two proteins: p21 and TREM2. That combination identifies them as senescent: cells that have stopped dividing but refuse to die, instead releasing a cocktail of inflammatory signals into their surroundings.
Cellular senescence has long been linked to aging and age-related disease in broad terms. What this study adds is specificity. Using multiomic profiling — a technique combining genomic, proteomic, and other molecular-level analyses simultaneously — the researchers pinpointed this exact subpopulation in both human liver tissue and mouse models. They then showed that these cells play a functional role in the development and worsening of metabolic dysfunction-associated steatotic liver disease, or MASLD, the condition formerly known as fatty liver disease or NASH.
Inflammaging: the slow burn of getting older
The term ‘inflammaging’ — a portmanteau of inflammation and aging — describes the state of chronic, low-grade inflammation that settles into the body as it ages. It’s not the acute, painful kind that comes with infection. It’s quieter and more corrosive, contributing to cardiovascular disease, diabetes, neurodegeneration, and, as this study shows, liver disease. The p21+TREM2+ macrophages appear to be one of the cellular engines driving that process.
For longevity research, the significance lies in the therapeutic potential. If senescence in this specific cell type drives liver disease and systemic inflammaging, then senolytics — drugs that selectively clear senescent cells — could, in theory, slow the progression. That idea is already being explored more broadly, but identifying precise cellular targets makes interventions sharper and potentially far more effective.
The causality question remains open
The study establishes presence and association, but the exact causal chain is not yet fully resolved. Are these senescent macrophages causing liver disease, or do they arise in response to it — and then accelerate its progression? That distinction matters enormously: the answer determines whether targeting these cells therapeutically makes sense. Future work will need to show whether eliminating them actually improves liver outcomes, and whether similar populations in other organs contribute to other age-related conditions. The machinery has been found; what it can be made to do is still being worked out.